Researchers analyzed HERBY trial data to uncover a subgroup of patients with MAPK pathway alterations who had increased overall survival.
A multi-region analysis of colorectal cancers suggests samples from opposite sides of a tumor can help trace early, invasiveness-related tumor characteristics.
The company said the disposal of these two businesses is part of a strategy to focus entirely on the molecular diagnostics market.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
The claim, enabling streamlined screening of pooled samples, follows updated industry recommendations for Zika virus screening in the US blood supply.
Last week, GenomeWeb's readers were most interested in Illumina Ventures' new investment in Luna DNA.
The lawsuit alleges Ancestry infringes 23andMe's method of matching relatives and damages its reputation via misleading online marketing.
Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.
A panel at the Biology of Genomes meeting discussed the ethical, legal, and social ramifications of germline gene editing.
Researchers used CRISPR-Cas9 screening assays in mouse and human cells to track down point mutations in the PARP1 gene that boost resistance to PARP inhibitor drugs.
Seventy-eight percent of participants had at least one positive carrier screening result and 3.5 percent had a medically actionable secondary finding.
The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.
Baylor College of Medicine's Olga Dudchenko sad the approach could assemble de novo mammalian genomes for less than $1,000.
With genome-wide association study data, researchers saw enrichment for schizophrenia-linked SNPs in human-specific differentially methylated regions.
The revenue increase was primarily driven by collaborative development services activities with partners including Qiagen.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
A study of more than 5,000 breast cancer patients found that multi-gene sequencing has rapidly replaced BRCA1/2-only tests, resulting in better pathogenic variant detection but also higher VUS rates.
The Ivy Glioblastoma Atlas includes newly generated anatomical and transcriptional profiles for dozens of tumors, combined with genomic data from TCGA.
Dramatic genetic diversity in Mycobacterium leprae isolates from medieval Europe could point to a long history or potential origins on the continent.
BC Platforms will incorporate Sentieon's next-generation sequencing data-processing software into its integrated genomics and clinical data products.
The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.
An international team found that survival estimates differed significantly between patients with germline mutations in different medulloblastoma predisposition genes.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.